9 hours Ago By ABMN Staff
Geode Capital Management LLC raised its position in Sana Biotechnology, Inc. ( NASDAQ:SANA – Free Report ) by 0.8% in the fourth quarter, HoldingsChannel.
com reports. The institutional investor owned 3,193,081 shares of the company’s stock after purchasing an additional 26,601 shares during the period. Geode Capital Management LLC’s holdings in Sana Biotechnology were worth $5,206,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology during the 3rd quarter valued at approximately $29,000. Blue Trust Inc.
grew its position in shares of Sana Biotechnology by 51.0% during the fourth quarter. Blue Trust Inc.
now owns 19,823 shares of the company’s stock worth $32,000 after buying an additional 6,694 shares in the last quarter. Ieq Capital LLC acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth approximately $32,000. KLP Kapitalforvaltning AS bought a new stake in shares of Sana Biotechnology in the fourth quarter worth $39,000.
Finally, Stifel Financial Corp acquired a new stake in Sana Biotechnology in the third quarter valued at $43,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.
Sana Biotechnology Stock Performance Shares of SANA opened at $1.77 on Friday. The firm has a fifty day moving average of $2.
12 and a 200-day moving average of $2.63. The company has a market cap of $398.
29 million, a price-to-earnings ratio of -1.26 and a beta of 1.78.
Sana Biotechnology, Inc. has a 1 year low of $1.26 and a 1 year high of $10.
50. Wall Street Analysts Forecast Growth SANA has been the subject of several recent analyst reports. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday, March 14th.
They set a “buy” rating and a $7.00 price objective for the company. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.
00 price objective for the company in a report on Tuesday, March 18th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Sana Biotechnology in a research note on Thursday.
Finally, TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.
80. Check Out Our Latest Research Report on SANA Sana Biotechnology Profile ( Free Report ) Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Articles Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. ( NASDAQ:SANA – Free Report ).
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter ..
